<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772265</url>
  </required_header>
  <id_info>
    <org_study_id>WosulinN/PK-PD/HV/FDA/10/v3</org_study_id>
    <nct_id>NCT00772265</nct_id>
  </id_info>
  <brief_title>Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects</brief_title>
  <official_title>A Randomized Single Center Double Blind 2 Period Crossover Glucose Clamp Study to Test for Bioequivalence Between 2 Recombinant Human Isophane Insulins Wockhardt's Human Isophane Insulin Injection100IU/ml With Novolin N in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to demonstrate bioequivalence of Wosulin N to Novolin® N with regard&#xD;
      to its total and to its maximum serum insulin concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is is to test for bioequivalence based on AUC0-24h and Cmax between&#xD;
      Wosulin N and Novolin® N.The study also compares the pharmacokinetic and pharmacodynamic&#xD;
      profiles as well as assessing safety and local tolerability of the two insulin preparations&#xD;
      in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean AUC0-24h and Cmax</measure>
    <time_frame>Visit 2 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK endpts: AUC0-4h, AUC0-6h, AUC0-12h, AUC6-12h, AUC6-24h,tmax,and elimination rate constant. PD endpoints: AUCGIR0-4h, AUCGIR0-6h, AUCGIR0-12h,AUCGIR0-24h, AUCGIR6-12h, AUCGIR6-24h, GIRmax and tGIRmax Safety : AEs,haematology,biochem,phy exam.</measure>
    <time_frame>Visit 2,3 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Wosulin N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novolin N</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wosulin N</intervention_name>
    <description>Total Dose per subject will be 0.4IU/Kg given Subcutaneously.</description>
    <arm_group_label>Wosulin N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novolin N</intervention_name>
    <description>Total dose per subject will be 0.4 IU/Kg given Subcutaneously.</description>
    <arm_group_label>Novolin N</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subject.&#xD;
&#xD;
          -  Age more than 18 and less than 45 years.&#xD;
&#xD;
          -  Considered generally healthy upon completion of medical history, physical examination&#xD;
             and biochemical investigations as judged by the Investigator.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Non-smoker, defined as no nicotine consumption for at least one year.&#xD;
&#xD;
          -  Signed and dated informed consent obtained before any trial-related activities.&#xD;
             (Trial-related activities are any procedure that would not have been performed during&#xD;
             normal management of the subject.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in this trial or other clinical trials within the last 30 days.&#xD;
&#xD;
          -  Pregnant, breast-feeding or intention of becoming pregnant or not using adequate&#xD;
             contraceptive measures (defined as intrauterine device (IUD) that has been in place&#xD;
             for at least 3 months, double barrier contraception, sterilization or abstinence, or&#xD;
             oral contraceptive pill, which should have been taken without difficulty for at least&#xD;
             3 months, or an approved hormonal implant).&#xD;
&#xD;
          -  Clinically significant abnormal haematology or biochemistry screening tests, as judged&#xD;
             by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT &gt;&#xD;
             2 times the upper limit of normal) or impaired renal function (elevated serum&#xD;
             creatinine values above the upper limit of normal) will not be allowed to enter the&#xD;
             trial.&#xD;
&#xD;
          -  Any serious systemic infectious disease during the four weeks prior to the first dose&#xD;
             of test drug, as judged by the Investigator.&#xD;
&#xD;
          -  History of any illness that, in the opinion of the Investigator, might confound the&#xD;
             results of the trial or pose risk in administering the trial drug to the subject. In&#xD;
             particular, subjects with significant cardiovascular disease, anemia (haemoglobin&#xD;
             below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the&#xD;
             trial.&#xD;
&#xD;
          -  History of alcohol or drug abuse in the past five years and/or any positive test for&#xD;
             drugs of abuse at screening.&#xD;
&#xD;
          -  Any positive reaction of drugs of abuse.&#xD;
&#xD;
          -  Hepatitis B or C or HIV positive.&#xD;
&#xD;
          -  Use of prescription drugs within 3 weeks preceding the first dosing of insulin, except&#xD;
             for oral contraceptives/hormonal implants.&#xD;
&#xD;
          -  Use of any insulin product for therapeutic purposes in the past.&#xD;
&#xD;
          -  Use of non-prescription drugs, except routine vitamins, within 3 weeks prior to the&#xD;
             first dose of the test drug. Occasional use of acetaminophen is permitted.&#xD;
&#xD;
          -  Mental incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or co-operation.&#xD;
&#xD;
          -  Blood donation of more than 500 ml within the last 12 weeks.&#xD;
&#xD;
          -  History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction.&#xD;
&#xD;
          -  Known or suspected allergy to trial product or related products.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi Guthrie</last_name>
    <role>Study Chair</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for clinical Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <last_update_submitted>December 26, 2012</last_update_submitted>
  <last_update_submitted_qc>December 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Isophane insulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

